A5048370689- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Hepatitis B Virus Studies
- Nanoplatforms for cancer theranostics
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- Health, Medicine and Society
- Cancer Treatment and Pharmacology
- Effects of Radiation Exposure
- Cancer Genomics and Diagnostics
- Salivary Gland Tumors Diagnosis and Treatment
- Medication Adherence and Compliance
- Colorectal Cancer Treatments and Studies
- Bipolar Disorder and Treatment
- Bladder and Urothelial Cancer Treatments
- Lung Cancer Treatments and Mutations
- Single-cell and spatial transcriptomics
- Myasthenia Gravis and Thymoma
- COVID-19 and healthcare impacts
- Cervical Cancer and HPV Research
- BRCA gene mutations in cancer
- Peripheral Neuropathies and Disorders
- Immunodeficiency and Autoimmune Disorders
- Chemotherapy-related skin toxicity
Ludwig Cancer Research
2021-2024
University of Lausanne
2012-2024
University Hospital of Lausanne
2013-2023
Abstract Developing strategies to inflame tumors is critical for increasing response immunotherapy. Here, we report that low-dose radiotherapy (LDRT) of murine promotes T-cell infiltration and enables responsiveness combinatorial immunotherapy in an IFN-dependent manner. Treatment efficacy relied upon mobilizing both adaptive innate immunity depended on cytotoxic CD4+ CD8+ T cells. LDRT elicited predominantly cells with features exhausted effector cells, a subset expressing NKG2D exhibiting...
Adoptive cell therapy (ACT) using ex vivo–expanded tumor-infiltrating lymphocytes (TILs) can eliminate or shrink metastatic melanoma, but its long-term efficacy remains limited to a fraction of patients. Using longitudinal samples from 13 patients with melanoma treated TIL-ACT in phase 1 clinical study, we interrogated cellular states within the tumor microenvironment (TME) and their interactions. We performed bulk single-cell RNA sequencing, whole-exome spatial proteomic analyses pre-...
Abstract Complementary medicine (CM) is used by one third to half of cancer patients throughout the world. The objective this study was describe prevalence CM use and potential for interactions with treatments in an academic oncology centre. A cross-sectional conducted among undergoing current treatment. Among 132 included patients, 56% had since their diagnosis 45% were using during treatment at time survey. main green tea (35%), herbal homeopathy (27%), dietary supplements medicines (27%)....
Background OX40 is a costimulatory receptor upregulated on antigen-activated T cells and constitutively expressed regulatory (Tregs). INCAGN01949, fully human immunoglobulin G1κ anti-OX40 agonist monoclonal antibody, was designed to promote tumor-specific immunity by effector T-cell activation Fcγ receptor-mediated Treg depletion. This first-in-human study conducted determine the safety, tolerability, preliminary efficacy of INCAGN01949. Methods Phase I/II, open-label, non-randomized,...
Immune-checkpoint blockade (ICB) has shown significant efficacy across various tumor types. However, tumors with low intraepithelial T-cell infiltration, often referred to as cold tumors, are expected yield poor responsiveness ICB. We investigated the potential of low-dose radiotherapy (LDRT) enhance ICB responses in 25 patients multimetastatic immuneexcluded solid through a multi-cohort phase I clinical trial (RACIN). Primary endpoint was determine safety and tolerability combination...
Sebaceous carcinoma (SC) is an uncommon neoplasm manifesting itself either in the eyelid or extraocularly head and neck area. Surgery standard of care. Irradiation rarely proposed as monotherapy but frequently administered adjuvant regimen following surgical resection. There no known strategy concerning chemotherapeutic treatment highly aggressive recurrent - metastatic forms disease. Our patient presented with SC scalp recurring after multiple excisions local radiotherapy. Chemotherapy...
<h3>Background</h3> A majority of patients with advanced NSCLC develop disease progression first-line immune-checkpoint inhibitors (ICI) ± chemotherapy. In the setting ICI resistance, effective strategies to provide deep and durable responses are urgently needed. Lifileucel (LN-144) LN-145 centrally manufactured (cryopreserved drug-product, 22-day manufacturing process) autologous TIL products that have demonstrated activity in melanoma, cervical cancer, head neck carcinoma.<sup>1–4</sup>...
Abstract The profiles, specificity and dynamics of tumor-specific clonotypes that are associated with clinical response to adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TILs) remain unclear. Using single-cell RNA/TCR-sequencing, we tracked TIL from baseline tumors ACT products post-ACT blood tumor samples in melanoma patients treated TIL-ACT. Patients responses had enriched tumor-reactive TILs, which were more effectively mobilized upon vitro expansion, yielding higher...
The influence of anti-T-cell therapy in the immunogenicity influenza vaccine kidney transplant recipients remains unclear.During 2010 to 2011 season, we evaluated immune response inactivated trivalent having received Thymoglobulin or basiliximab as induction therapy. A hemagglutination inhibition assay was used assess vaccine. primary outcome geometric mean titers after vaccination.Sixty patients (Thymoglobulin n=22 and n=38) were included. Patients group older (P=0.16), showed higher...
Background The strengthening or substitution of intravenous cytotoxic chemotherapy cycles by oral targeted anticancer therapies, such as protein kinase inhibitors (PKIs), has provided impressive clinical benefits and autonomy well a better quality life for patients with cancer. Despite these advances, adverse event management at home medication adherence remain challenging. In addition, PKI plasma concentrations vary significantly among cancer receiving the same dosage, which could explain...
Abstract Adoptive cell therapy (ACT) using ex vivo expanded tumor-infiltrating T lymphocytes (TILs) can mediate responses in metastatic melanoma, but long-term efficacy remains limited to a fraction of patients. Here we interrogated tumor-microenvironment (TME) cellular states and interactions longitudinal samples from 13 melanoma patients treated with TIL-ACT our clinical study ( NCT03475134 ). We performed single-cell RNA-seq spatial proteomic analyses pre- post-ACT tumor tissues showed...
Endometrial cancer (EC) is a common gynecological malignancy and the fourth most in European North American women. Amongst EC, advanced serous, p53-mutated, pMMR subtypes have highest risk of relapse despite optimal standard care therapy. At present, there no maintenance treatment to prevent among these high-risk patients. Vaccines are form immunotherapy that can potentially increase immunogenicity pMMR, p53-mutated tumors render them responsive check point inhibitor-based immunotherapy. We...
Background Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TILs) is a promising experimental immunotherapy that has shown high objective responses in patients with melanoma. Current protocols use lymphodepletive chemotherapy before infusion of ex vivo expanded TILs, followed by high-dose interleukin-2 (IL-2). Treatment-related toxicities are mainly attributable to the regimen and IL-2 generally reversible. Neurological side effects have rarely been described. Nevertheless,...
Effets indésirables des inhibiteurs de points contrôle immunitaire : diagnostic et prise en charge Les nouvelles thérapies oncologiques, dont les immunitaire, permettent une stimulation lymphocytaire antitumorale.Ces traitements ont amélioré manière significative le pronostic oncologique nombreux patients, mais présentent néanmoins un nouveau spectre toxicités, d'ordre immunologique.Les toxicités immunes plus fréquentes sont rash cutané, la colite, dysthyroïdie, l'hypo physite, l'hépatite...
Abstract Purpose: This phase 1/2 trial evaluates the novel immunotherapy BMS-986253 in combination with immune checkpoint inhibitors (NCT03400332). Interleukin-8 (IL-8) is an immunosuppressive chemokine often elevated serum of patients cancer. High IL-8 concentration associated poor prognoses and resistance to immunotherapies, including anti-programmed death-1 (PD-1) anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) agents (Schalper et al. Nat Med 2020;26:688). The addition anti-IL-8 therapy...
2533 Background: Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) has demonstrated a curative potential for patients with metastatic melanoma (MM). Nevertheless, activity remains unsatisfactory in many patients, requiring development of biomarkers that predict therapeutic efficacy. We report results single-center phase I study to assess feasibility, safety and efficacy TIL-ACT MM (NCT03475134). Methods: Patients refractory at least one prior line received TIL...